Siemens Healthineers\u2019s INNOVANCE assays help improve efficiencies, workflow and resource management following a COVID-19 diagnosis.
\nIn hospitalised COVID-19 patients, elevated D-dimer levels have been found to be strongly associated with disease severity and even mortality reflecting the procoagulant status and high thrombotic risk observed in many COVID-19 patients. Therefore, the monitoring of D-dimer levels is recommended for hospitalised COVID-19 patients to stratify their thrombotic risk including testing for deep vein thrombosis and pulmonary embolism and guiding treatment over the course of the disease.
\nTreating COVID-19 patients with anticoagulants has been associated with improved outcomes, both in and out of the intensive care unit setting.
\nAccurate antithrombin measurement in COVID-19 patients undergoing anticoagulant treatment may be useful to determine the efficacy of anticoagulant therapy as antithrombin levels might be reduced.
\nSiemens Healthineers has a comprehensive portfolio of assays for detection and monitoring of coagulation disorders.
\nFor more information, visit: https:\/\/www.siemenshealthineers.com\/hemostasis\/ innovance-reagents-for-coagulation-disorders<\/link>\n
\nSupplier:<\/strong> Siemens Healthineers
\nWebsite:<\/strong> <\/a><\/p>\n
Mail the supplier<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"